Literature DB >> 11877032

[A comparative study on the expressions of IL-4, IFN-gamma and TNF-alpha in BMMNC of acute and chronic aplastic anemia patients].

T Zhang1, B Sun, Q Feng, Y Yuan, H Zhu, L Liu.   

Abstract

OBJECTIVE: To detect the induced levels of IL-4, IFN-gamma and TNF-alpha in the supernatant of bone marrow mononuclear cells (BMMNC) and compare the difference of immune status between acute (SAA) and chronic (CAA) aplastic anemia patients.
METHODS: Concentrations of IL-4, IFN-gamma and TNF-alpha in PHA-P-induced BMMNC supernatants were determined by ELISA assay in 11 SAA and 13 CAA patients as well as 16 controls. Concentration differences between the two groups were compared.
RESULTS: (1) The IFN-gamma and TNF-alpha levels in AA patients studied were much higher than that in controls, and IL-4 levels were normal in SAA group but elevated in CAA group. (2) TNF-alpha levels were comparable between the two AA groups, but both IL-4 and IFN-gamma levels were significantly different between them.
CONCLUSION: Enhanced cellular immunity seems to play an important role in the pathogenesis of SAA, and enhancement of both cellular and humoral immunity might contribute to the pathogenesis of CAA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11877032

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  2 in total

1.  Bone marrow angiogenesis in patients presenting with differential Chinese medicine syndrome: correlation with the clinico-pathological features of aplastic anemia.

Authors:  Di-jiong Wu; Bao-dong Ye; Zhi-ping Hu; Yi-ping Shen; Jian-ping Shen; Sheng-yun Lin; Ming-tao Chen; Yong-lin Liu; Yu-hong Zhou
Journal:  Chin J Integr Med       Date:  2013-12-05       Impact factor: 1.978

2.  Clinical study on effect of Astragalus Injection and its immuno-regulation action in treating chronic aplastic anemia.

Authors:  Mao-sheng Wang; Jun Li; Hai-xia Di; Zhen-li Li; Shu-Lian Yang; Wei Hou; Jin-yu Yan; Xiao-min Zhao
Journal:  Chin J Integr Med       Date:  2007-06       Impact factor: 1.978

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.